Across a continent where 64 million people carry chronic hepatitis B and fewer than one in a hundred receive treatment, Africa CDC has released a practical operational toolkit designed not for specialists but for nurses in district clinics far from any hospital. The tools to prevent and cure this disease have existed for decades — the vaccine costs cents, the medicines are off patent — and so the deaths that continue to accumulate are not the product of ignorance but of deferred choice. This toolkit arrives as a test of Africa's broader commitment to health sovereignty: the belief that the con
Africa's Hepatitis Crisis Tests Health Sovereignty Agenda
272,000 hepatitis B deaths in Africa in 2022; millions living with chronic infection with minimal access to screening or treatment.
Every death was preventable. The gap is not knowledge—it is choice.
Mark
Why does hepatitis matter more than other diseases right now?
Mimi
Because it's the simplest test of whether Africa can actually govern its own health. The vaccine costs pennies. The cure rate is over 95 percent. We've had the tools for decades. If we can't organize around something this straightforward and this affordable, we'll fail at the harder problems ahead.
Mark
But 64 million people are infected. That's enormous. How do you even start?
Mimi
You start where Egypt started—with screening. They screened 50 million people. Once you know who is infected, you can link them to treatment. Rwanda decentralized it, letting nurses handle uncomplicated cases in village clinics instead of waiting for specialists. Uganda put three million dollars a year of their own money into it. The pattern is the same everywhere it works: political will first, then domestic money, then partnerships.
Mark
What's the real obstacle? Money?
Mimi
Not entirely. The medicines are off patent. The diagnostics are simple. The real obstacle is that for decades, Africa assumed someone else would pay for this. Now we're saying: we will. That's a different kind of problem. It requires political commitment, not just resources.
Mark
What happens if countries don't act?
Mimi
The deaths continue. Cirrhosis. Liver cancer. Lost productivity. Higher health costs down the line. But more than that—it signals that Africa still can't organize itself around its own priorities. That undermines the entire sovereignty agenda.
Mark
Is there a timeline?
Mimi
2030. The African Union set that as the target for eliminating vertical transmission—mother-to-child transmission. But that's just the beginning. Elimination itself is the longer goal. The toolkit we released this week is meant to accelerate the work between now and then.
Mark
Who's actually going to read this toolkit?
Mimi
Nurses in district clinics. Health workers in primary care facilities. People who don't have access to specialists but need to make clinical decisions every day. That's who it's for. It translates what the WHO knows into what a health worker in a rural setting can actually do.
Der Puls
- 272,000 Africans died of hepatitis B in 2022 alone — preventable deaths from a disease with cheap vaccines and off-patent treatments that most infected people never knew they had.
- Fewer than 5% of infected Africans have ever been screened, and fewer than 1% receive treatment, exposing a system gap that is not scientific but political and structural.
- As development aid shrinks and geopolitical uncertainty deepens, Africa can no longer assume external funding will fill these gaps — the health sovereignty agenda is a response to that fragile dependency.
- The new Africa CDC toolkit translates WHO guidance into clinical decision trees and treatment protocols a rural nurse can use today, without waiting for a specialist or a donor.
- Egypt, Rwanda, and Uganda have each demonstrated that political commitment and domestic financing — not foreign aid — are the decisive variables in achieving elimination.
- The path forward runs through five demands: domestic financing innovation, local manufacturing, primary care integration, regional cooperation, and community-driven demand for testing.
Across a continent where 64 million people carry chronic hepatitis B and fewer than one in a hundred receive treatment, Africa CDC has released a practical operational toolkit designed not for specialists but for nurses in district clinics far from any hospital. The tools to prevent and cure this disease have existed for decades — the vaccine costs cents, the medicines are off patent — and so the deaths that continue to accumulate are not the product of ignorance but of deferred choice. This toolkit arrives as a test of Africa's broader commitment to health sovereignty: the belief that the continent must lead, finance, and deliver its own health future rather than wait for external rescue. Egypt, Rwanda, and Uganda have already proven the path is walkable; the question now is whether the will to walk it will spread.
Africa carries nearly two-thirds of the world's new hepatitis B infections, with 64 million people living with the chronic disease and 272,000 dying from it in 2022 alone. Fewer than five in a hundred infected Africans have been screened, and fewer than one in a hundred receive treatment — not because the tools are unavailable, but because the choices to deploy them have not been made. The vaccine costs cents. The medicines are off patent. Every death was preventable.
This week, Africa CDC released an Operational Toolkit for the Prevention, Diagnosis and Management of Hepatitis B — a practical, clinical document built for a nurse in a district facility hundreds of kilometres from the nearest specialist. It contains treatment algorithms, fibrosis assessment protocols, and decision support designed for real conditions in resource-limited settings. It is not a policy aspiration. It is a working instrument.
The toolkit's release reflects a deeper continental shift. With development assistance contracting and geopolitical uncertainty rising, Africa's Health Security and Sovereignty agenda has committed the continent to leading its own health priorities — financing what it can finance, producing what it can produce, and setting its own course. Viral hepatitis is the clearest test of that commitment: if Africa cannot organize around interventions this affordable and this proven, harder challenges will follow.
Some countries have already shown the way. Egypt screened more than 50 million citizens and became the first nation to reach WHO gold tier status on hepatitis C elimination. Rwanda made treatment free, decentralized services, and authorized nurses to manage uncomplicated cases. Uganda allocates roughly three million dollars annually in domestic funds for free testing, treatment, and monitoring. The pattern across all of them is the same: political leadership first, domestic money second, partnership third.
The continental infrastructure exists. Nearly every African Union member state has integrated hepatitis B vaccination into childhood immunization. The AU has adopted a plan to eliminate vertical transmission of HIV, syphilis, and hepatitis B by 2030 through a single antenatal visit. Since 2022, a continental programme has helped 32 member states learn directly from Egypt's experience.
What remains is a set of decisions: to fund health systems through solidarity levies and health bonds rather than donor dependency; to build local manufacturing with reliable markets; to integrate hepatitis services into primary care and digital systems; to deepen regional cooperation; and to invest in community awareness that reduces stigma and drives demand. Success will look unremarkable — a newborn vaccinated before leaving the ward, a pregnant woman learning her status at her first clinic visit, a rural nurse knowing exactly which patient needs treatment. None of it requires a breakthrough. All of it requires a choice that Egypt, Rwanda, and Uganda have already made.
Africa has 64 million people living with chronic hepatitis B. In 2022 alone, the virus killed 272,000 of them. The continent accounts for nearly two-thirds of all new hepatitis B infections worldwide. Yet fewer than five in every hundred infected Africans have been screened for the disease, and fewer than one in a hundred receive treatment. The tools to prevent, diagnose, and cure hepatitis have existed for decades. The vaccine costs cents. The medicines are off patent. The diagnostics are straightforward. Every death was preventable. The gap between what Africa knows and what Africa does is not a knowledge problem—it is a choice.
This week, the Africa Centres for Disease Control and Prevention released an Operational Toolkit for the Prevention, Diagnosis and Management of Hepatitis B. It is not a theoretical document. It contains treatment algorithms, liver fibrosis assessment protocols, and clinical decision support designed for a nurse working in a district facility where the nearest specialist lives hundreds of kilometres away. The toolkit translates World Health Organization recommendations into something a health worker can actually use in daily practice. It exists because the continent has decided to stop waiting for someone else to solve this problem.
That decision reflects a larger shift. Development assistance is shrinking. Disease outbreaks are becoming more frequent. Geopolitical uncertainty has deepened. Africa can no longer assume that external funding will sustain its health systems. The continent's Health Security and Sovereignty agenda emerged from this reality—a commitment that African nations will lead their own health priorities, finance what they can afford to finance, produce what they can produce domestically, and set their own course. Viral hepatitis is the clearest test of whether this agenda actually works. If Africa cannot organize itself around interventions this cheap and this proven, the harder challenges ahead will overwhelm the continent.
Some countries are already showing what is possible. Egypt screened more than 50 million citizens through its 100 Million Healthy Lives campaign and became the first nation anywhere to reach World Health Organization gold tier status on the path toward hepatitis C elimination. Rwanda screened more than seven million people, made hepatitis C treatment free nationwide, decentralized services, and authorized trained nurses to manage uncomplicated cases in primary health facilities. Uganda allocates approximately three million dollars annually in domestic resources for free hepatitis B testing, treatment, and viral load monitoring. Nigeria, Senegal, Ghana, and Cameroon have each charted their own routes to elimination through different financing and delivery models. The pattern is identical across all of them: political leadership comes first, domestic money comes second, and partnership comes third.
The continental infrastructure is already in place. Nearly every African Union member state has introduced hepatitis B vaccination into routine childhood immunization. The African Union adopted the Africa Plan Towards the Elimination of Vertical Transmission of HIV, Syphilis and Hepatitis B by 2030, treating three infections as a single problem to be solved through the same antenatal visit. Since 2022, with support from the Korea International Cooperation Agency, the Continental Viral Hepatitis Prevention and Control Programme has established a continental expert group, completed the first assessment of national hepatitis programmes, and helped 32 member states learn directly from Egypt's experience.
Moving forward requires action in five areas. First, African nations must increase domestic financing through innovative mechanisms—solidarity levies, health security bonds, diaspora bonds, taxes on tobacco and alcohol—while reducing reliance on external aid. Second, the continent must strengthen local manufacturing and pooled procurement so that vaccines, diagnostics, and antiviral medicines produced by qualified African manufacturers have reliable markets and secure supply chains. Third, hepatitis services must be integrated into primary health care and digital systems, ensuring every newborn receives the hepatitis B birth dose on time and every pregnant woman is screened. Fourth, member states must deepen regional cooperation and share expertise to scale proven interventions. Fifth, public awareness and community engagement must reduce stigma and increase demand for testing and vaccination.
Success will look ordinary. A newborn vaccinated before leaving the hospital ward. A pregnant woman learning her hepatitis status at her first antenatal visit. A nurse in a rural clinic knowing which patient needs treatment and which needs monitoring. A person diagnosed and treated before cirrhosis or liver cancer develops. A diagnostic test manufactured on the African continent, procured with African money, in the hands of a health worker paid by an African treasury. None of this requires a scientific breakthrough. All of it requires a decision. Egypt, Rwanda, and Uganda have already made that decision and proven what it produces. The question now is whether the rest of the continent will follow.
Bemerkenswerte Zitate
Health sovereignty does not mean isolation. It signals a new model of partnership in which African nations lead with clarity and confidence, finance what they can finance, produce what they can produce, and set their own priorities.— Dr. Jean Kaseya, Director General, Africa CDC
If Africa cannot organise itself around interventions this affordable and this proven, the harder tests ahead will defeat us.— Dr. Jean Kaseya, Director General, Africa CDC
Möchten Sie die ganze Geschichte?
Das Original lesen bei pan african visions ↗
Health & Medicine